There are currently 1995 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
NCT06041594
Recruiting
This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System. These devices are manufactured by Innova Vascular, Inc.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/30/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Pulmonary Embolism
Register for Updates
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
NCT05364086
Recruiting
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: John H Stroger Jr Hospital of Cook County, Chicago, Illinois
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science
NCT00950118
Recruiting
The goal of this study is to identify genes that convey susceptibility to congenital diaphragmatic hernia in humans. The identification of such genes, and examination of their structure and function, will enable a delineation of molecular pathogenesis and, ultimately, prevention or treatment of congenital diaphragmatic hernia. There are many different possible modes of inheritance for congenital anomalies, including autosomal dominant, autosomal recessive, and multifactorial. Multi-factorial inh... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/30/2025
Locations: Rush Hospital, Chicago, Illinois
Conditions: Congenital Diaphragmatic Hernia
Register for Updates
Measuring Surgical Recovery After Radical Cystectomy
NCT03193970
Recruiting
The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating institutions. The goals of this initiative are to obtain a detailed baseline of multiple patient-reported outcomes (PRO) and clinician-reported outcomes (CRO) as well as various presenting conditions associated with them, so that future quality improvement interventions can be evaluated accurately as to their relative contribut... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Bladder Cancer
Register for Updates
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
NCT05261139
Recruiting
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19). The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for... Read More
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
04/30/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois +1 locations
Conditions: COVID-19
Register for Updates
Exploring the Relationship Between Heart Rate Variability (HRV), Training Load, and Endurance Performance
NCT06964100
Recruiting
The ability of smart phones, aided by wearable devices (e.g. smart watches), to collect a variety of data, including physical activity, heart rate, and other exercise metrics, may provide a unique opportunity to understand real-world variability. The primary objective of this study is to test user engagement, app functionality, and feasibility of the newly developed Gatorade Sports Science Institute (GSSI) Labs App to conduct Real-World research studies. The secondary purpose of this study is to... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/30/2025
Locations: Remote study, no physical site. Managed by Gatorade Sports Science Institute. Do not contact investigators to enroll. Recruitment is handled by an independent agency., Chicago, Illinois
Conditions: Heart Rate Variability
Register for Updates
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05563220
Recruiting
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Northwestern Feinberg Scholl of Medicine Prentice Women's Hospital, Chicago, Illinois
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
The Periviable GOALS Decision Support Tool
NCT05264779
Recruiting
The Periviable GOALS (Getting Optimal Alignment around Life Support) decision support tool (DST) is meant to facilitate informed shared decision-making regarding neonatal resuscitation for families facing the threat of a periviable delivery (deliveries occurring between 22 0/7 - 25 6/7 weeks gestational age). It is designed for parents to review independent of their clinician, and is intended to supplement, not replace, clinician counseling. The focus of the DST is the provision of patient-cente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Pregnancy Preterm, Premature Birth, Pregnancy Complications, Obstetric Labor, Premature, Obstetric Labor Complications
Register for Updates
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
NCT05096481
Recruiting
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, a... Read More
Gender:
ALL
Ages:
Between 3 years and 39 years
Trial Updated:
04/30/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Register for Updates
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
NCT04929028
Recruiting
This phase II trial studies the side effects of chemotherapy and intensity modulated radiation therapy in treating patients with low-risk HIV-associated anal cancer, and nivolumab after standard of care chemotherapy and radiation therapy in treating patients with high-risk HIV-associated anal cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: University of Illinois, Chicago, Illinois
Conditions: AIDS-Related Anal Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Anal Margin Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Anal Non-Keratinizing Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8
Register for Updates
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
NCT05538208
Recruiting
The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily to achieve an area under the concentration-time curve (AUC0-12h) of MPA \>60-70 mg\*h/L. The study goal is to determine the safety and efficacy of MMFPK compared to MMFBSA for the treatment of prolifer... Read More
Gender:
ALL
Ages:
Between 8 years and 20 years
Trial Updated:
04/30/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois +1 locations
Conditions: Lupus Nephritis
Register for Updates
An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy
NCT06270719
Recruiting
This is a multicenter, prospective, observational Phase 4 study in the United States. The study is designed to collect both medical history and prospective data on Duchenne muscular dystrophy (DMD) treatment outcomes in participants receiving delandistrogene moxeparvovec as part of clinical care, compared to participants with DMD receiving or prescribed to start chronic glucocorticoid treatment at baseline in routine clinical practice.
Gender:
MALE
Ages:
4 years and above
Trial Updated:
04/30/2025
Locations: Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois
Conditions: Duchenne Muscular Dystrophy
Register for Updates